Sunovion presents schizophrenia drug Latuda PEARL 3 study results
The PEARL 3 study was part of an extensive worldwide clinical development program involving more than 2,900 subjects, which evaluated the safety and efficacy of Latuda. In this
Australia-based Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35bn, combining Telix’s operations with ITM’s radioisotope production business and late-stage treatment candidate ITM-11.
Cambridge Research & Instrumentation develops and markets optical imaging systems to advance biomedical research and molecular-based drug and diagnostic development. CRi’s patented preclinical and tissue-based multiplexed analysis systems